Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Date:3/4/2008

urities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com

INSMED I
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
2. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
3. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed to Appeal Delisting Notification From Nasdaq
6. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
7. Insmed Appoints Dennis M. Lanfear to Board Of Directors
8. Barr Announces Favorable Ruling in Yasmin(R) Patent Challenge
9. Vermillion Announces Effectiveness of Reverse Stock Split
10. Rosetta Genomics Announces Allowance of Two Additional microRNA Patents
11. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
(Date:11/26/2014)... Silicon Valley Electronic Data Capture (EDC) provider ... provider of clinical research and data management services to ... its CRO Partnership Program, Clinovo expands ClinCapture , ... , “We have found Clinovo’s ClinCapture to exceed our ... is both user friendly and easy to deploy. The ...
(Date:11/26/2014)... November 26, 2014 SoundConnect , ... is proud to announce that Darren Suders has joined ... Darren will drive the partner program ... experience. , Darren brings more than 10-years ... key roles in channel operations, from policy development, to ...
(Date:11/26/2014)... Theravalues Corporation annuncia con orgoglio il lancio di Theracurmin® ... Europe 2014 (dal 2 al 4 dicembre, ... con la maggiore biodisponibilità di sempre, con una combinazione ... norme europee. La curcumina è un pigmento ... longa ) che è stata associata con attività antiossidanti, ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... 2008 The American Ceramic Society and the ... released ACerS-NIST Phase Equilibria Diagrams CD-ROM Database (Version ... evaluated phase diagrams of ceramic systems such as ... chalcogenides, and features over 1,000 new diagrams. , ...
... Directors of Schering-Plough Corporation (NYSE: SGP ) today declared ... will be made on Feb. 27, 2009, to shareholders of record ... of Sept. 30, 2008, there were 1,626,234,628 common shares outstanding. ... today also declared a quarterly dividend of $3.75 per share on ...
... Dec. 10 Nuvelo, Inc.,(Nasdaq: ... the Phase 1 trial of,recombinant, secreted protein, ... Wnt,Therapeutics Program. This single-center, double-blind, placebo-controlled,single-ascending dose ... of a single intravenous (IV) administration of ...
Cached Biology Technology:The American Ceramic Society releases new ACerS-NIST phase equilibria diagrams CD-ROM database 2Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 2Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 3Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 4Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers 5
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the ... phase. In its first six months of existence, the Lab ... evidence support for local law enforcement. "Because our ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/5/2014)... professor of biology in the UTSA College of ... nation selected to receive a two-year $300,00 National ... Research (EAGER). The funding supports President Obama,s BRAIN ... create new technology that will demystify complex brain ... in neuroscience are broken into the interactions of ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... Four million people die every year from respiratory diseases such as ... dangerous. What is more, the flu vaccine is not as effective ... reason for this is that with age the fire power of ... largely unknown. An international EU project led by the University of ...
... vitamin in an attempt to defeat drug screening tests may ... from The Children's Hospital of Philadelphia and The University of ... toxic side effects from taking large amounts of niacin, also ... drug tests. , Both adult patients suffered skin ...
... technique pioneered by Dr Amanda Hayes and her UNSW ... cells to airborne toxicants and measures cytotoxic effects. The ... a small diffusion chamber and then exposed to selected ... exposure, they can study cell growth and metabolism, and ...
Cached Biology News:Fighting influenza & co. with 40,000 blood samples 2Fighting influenza & co. with 40,000 blood samples 3Misusing vitamin to foil drug test may be toxic; plus, it doesn't work 2Soft-cell approach cuts animal tests 2Soft-cell approach cuts animal tests 3
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Human VEGF-D Biotinylated MAb (Clone 78923)...
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Biology Products: